ArticleArthritis & rheumatology (Hoboken, N.J.)2026

Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.

Derin Karacabeyli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.